Phibro Animal Health (NASDAQ:PAHC) Cut to “Buy” at StockNews.com

StockNews.com cut shares of Phibro Animal Health (NASDAQ:PAHC) from a strong-buy rating to a buy rating in a research note published on Friday.

A number of other brokerages also recently commented on PAHC. Morgan Stanley lifted their price objective on Phibro Animal Health from $20.00 to $25.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 17th. Barclays boosted their target price on shares of Phibro Animal Health from $13.00 to $20.00 and gave the company an “underweight” rating in a report on Tuesday, November 12th. Bank of America lifted their price target on shares of Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a report on Friday, August 30th. Finally, JPMorgan Chase & Co. started coverage on Phibro Animal Health in a report on Tuesday, September 10th. They set a “neutral” rating and a $22.00 price objective for the company. Two analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $20.50.

Phibro Animal Health Stock Performance

NASDAQ:PAHC opened at $21.05 on Friday. Phibro Animal Health has a 1-year low of $10.03 and a 1-year high of $25.98. The firm has a 50 day simple moving average of $23.29 and a 200-day simple moving average of $20.89. The firm has a market cap of $852.59 million, a PE ratio of 48.95, a P/E/G ratio of 0.58 and a beta of 0.51. The company has a debt-to-equity ratio of 1.81, a current ratio of 3.23 and a quick ratio of 1.69.

Phibro Animal Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 18th. Stockholders of record on Wednesday, November 27th were paid a dividend of $0.12 per share. The ex-dividend date was Wednesday, November 27th. This represents a $0.48 annualized dividend and a dividend yield of 2.28%. Phibro Animal Health’s dividend payout ratio is presently 111.63%.

Institutional Trading of Phibro Animal Health

Several institutional investors and hedge funds have recently bought and sold shares of the company. Sofinnova Investments Inc. acquired a new stake in shares of Phibro Animal Health in the second quarter valued at approximately $3,975,000. American Century Companies Inc. increased its holdings in shares of Phibro Animal Health by 119.6% during the second quarter. American Century Companies Inc. now owns 347,191 shares of the company’s stock valued at $5,822,000 after purchasing an additional 189,068 shares during the period. Jacobs Levy Equity Management Inc. raised its stake in shares of Phibro Animal Health by 116.6% during the third quarter. Jacobs Levy Equity Management Inc. now owns 192,255 shares of the company’s stock valued at $4,330,000 after purchasing an additional 103,491 shares in the last quarter. Dana Investment Advisors Inc. grew its position in Phibro Animal Health by 17.2% in the 2nd quarter. Dana Investment Advisors Inc. now owns 513,926 shares of the company’s stock valued at $8,619,000 after buying an additional 75,546 shares in the last quarter. Finally, Algert Global LLC raised its position in shares of Phibro Animal Health by 521.1% during the 3rd quarter. Algert Global LLC now owns 71,335 shares of the company’s stock worth $1,606,000 after buying an additional 59,850 shares in the last quarter. Institutional investors and hedge funds own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.